Nephros, Inc.

Type: Public
On the web: http://www.nephros.com
Employees: 11
Employee growth: (15.4%)

Nephros develops and makes medical devices that are used to treat irreversible loss of kidney function associated with End Stage Renal Disease, or ESRD. ESRD is often the result of other health problems such as diabetes and high blood pressure. The company's products are designed to replace a patient's kidney function with the device system. Nephros is positioning its therapeutic devices as an alternative to hemodialysis, the most common form of renal replacement therapy. The company's products use a process called "hemodiafiltration" (HDF) combining hemodialysis with hemofiltration to clean the patient's blood.

Key numbers for fiscal year ending December, 2008:
Sales: $1.5M
One year growth: 23.2%
Net income: ($6.3)M

Officers:
Chairman: James S. (Jim) Scibetta
President, CEO, and Director: Ernest A. Elgin III
CFO: Gerald J. (Jerry) Kochanski

Competitors:
Fresenius Medical Care
Gambro AB
Sorin

Policy introduced in the Soviet Union in March 1921 in place of rigid central controls. It envisaged the end of grain requisitioning and the development of limited market relations in trade and industry. Originally a ‘breathing space’, it was then considered by many Bolsheviks, especially Bukharin, as a long-term strategy for the transition to socialism.

— Stephen Whitefield